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Angiotensin II stimulates the formation of reactive oxygen
species by increased NADPH oxidase activity, which
contributes to proapoptotic and profibrotic mechanisms
critical in renal injury. Here we determine if apocynin, an
inhibitor of NADPH oxidase, interferes with the action of the
intrarenal renin–angiotensin system to minimize the
progression of renal disease. Transgenic mice that
overexpress rat angiotensinogen in their proximal tubule
cells were given either apocynin, perindopril, or hydralazine
while untreated or apocynin-treated non-transgenic
littermates served as controls. Untreated transgenic mice had
significant elevations of their systolic blood pressure,
albuminuria, reactive oxygen species production, NADPH
oxidase activity, tubular apoptosis, active caspase-3, Bax,
transforming growth factor-b1, plasminogen activator
inhibitor-1, extracellular matrix proteins, collagen type IV,
and phosphorylated p47phox expression compared to
untreated non-transgenic mice. Apocynin and perindopril
blunted these changes; however, apocynin had no effect on
the systolic blood pressure whereas hydralazine prevented
hypertension and tubulointerstitial fibrosis but not proximal
tubule cell apoptosis. Our study shows that the intrarenal
renin–angiotensin system stimulates proximal tubule cell
apoptosis and tubulointerstitial fibrosis, in part, by enhanced
NADPH oxidase activity and reactive oxygen species
generation independent of systemic hypertension.
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Although the progression of chronic renal failure may be
initiated by glomerular injury, studies over the past three
decades have demonstrated that tubulointerstitial injury,
characterized by interstitial fibrosis and tubular atrophy, may
be a better predictor of renal disease progression than
glomerular pathology.1–6 Tubular atrophy has been observed
in various experimental models of nephropathy as well as in
human renal diseases,7–12 including diabetic nephropa-
thy.13,14 However, the pathogenesis of tubular atrophy
remains poorly understood.
Apoptosis, postulated to be involved in the pathogenesis
of tubular atrophy, mediates renal cell death in various renal
diseases, including glomerulosclerosis,15 polycystic kidney
disease,16 ischemic renal disease,17 allograft nephropathy,18
and diabetes.19 The concept that apoptosis may mediate
tubular atrophy is appealing because, unlike ischemia, which
commonly leads to necrosis, apoptosis promotes cell removal
with minimal inflammation.20 The prevalence of apoptotic
renal proximal tubular cells (RPTCs) without concomitant
RPTC hyperplasia suggests that net RPTC deletion by
apoptosis may be important in the pathogenesis of tubular
atrophy in chronic kidney diseases.
Enhanced reactive oxygen species (ROS) production also
has been implicated in the progression of various renal
diseases,21–23 including diabetic nephropathy.24 In vitro, ROS
contribute to apoptosis of podocytes, mesangial and tubular
cells exposed to high glucose.25–27 Angiotensin II (Ang II) is a
potent stimulator of ROS generation by heightened NADPH
oxidase activity in mesangial cells and RPTCs, and antiox-
idants appear to provide renal protection, in part, by
ameliorating oxidative stress induced by Ang II.28–30 Such
observations strongly indicate a causal link between Ang II,
ROS, and apoptosis within the kidney.
We previously documented that transgenic (Tg) mice
overexpressing rat angiotensinogen (Agt), the sole precursor
of angiotensins, in their RPTCs are prone to develop
hypertension, albuminuria, and renal injury.31 This study
investigated whether ROS generation mediates the proapop-
totic and profibrotic effects engendered by upregulation of
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 28 December 2007; revised 8 August 2008; accepted 19
August 2008; published online 15 October 2008
Correspondence: John S.D. Chan, Department of Medicine, Universite´ de
Montre´al, Centre hospitalier de l’Universite´ de Montre´al (CHUM)–Hoˆtel-Dieu,
Research Centre, Pavillon Masson, 3850 Saint Urbain Street, Montreal,
Quebec, Canada H2W 1T8. E-mail: john.chan@umontreal.ca
4Current address: Faculty of Biomedical Laboratory Science, Kaohsiung
Medical University, Kaohsiung, Taiwan, ROC.
156 Kidney International (2009) 75, 156–166
the intrarenal renin-angiotensin system (RAS) in proximal
tubules in vivo, and whether inhibition of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase with
apocynin (an inhibitor of NAPDH oxidase) could prevent
RPTC apoptosis, independently of systemic hypertension.
RESULTS
ROS generation, albuminuria and renal size in Tg mice
Tg mice exhibited significantly augmented in ROS generation
in their RPTCs (Figure 1a) and increased albumin/creatinine
ratios as compared to non-Tgs (Figure 1b), though their
kidney/body weight ratios were similar (Figure 1c). Treat-
ment with either apocynin or perindopril, but not with
hydralazine, normalized ROS generation and the urinary
albumin/creatinine ratio, but had no effect on the kidney/
body weight ratio (Figure 1a–c).
Hypertension in Tg mice
Mean systolic blood pressure (SBP) in male Tg mice
increased from week 11 of life, becoming statistically
significant at week 12 and thereafter (Figure 2a). Perindopril
and hydralazine (commenced at week 13) normalized the
SBP of Tg mice after 1 week of treatment (Figure 2a). In
contrast, apocynin did not significantly reduce SBP in Tg
mice (Figure 2a and b).
Renal morphology
Renal damage was evident in Tg mice (Figure 3b) as
compared to non-Tg mice (Figure 3a). Histologic findings
included vacuoles and loss of the brush border in RPTCs, a
large number of detached cells and accumulation of cellular
debris in the tubular lumen in Tg kidneys, indicating RPTC
damage. Some RPTCs were flattened or atrophied. Treatment
with apocynin (Figure 3c) or perindopril (Figure 3d)
markedly attenuated these abnormalities in Tg mice, whereas
hydralazine (Figure 3e) had minimal effect.
RPTC volume was significantly higher in untreated Tg
mice than in non-Tg littermates (Figure 3f). Treatment with
apocynin, perindopril, or hydralazine effectively attenuated
this change. Glomerular volume did not differ significantly
between Tg and non-Tg mice, and was unaffected by
apocynin, perindopril or hydralazine treatment (Figure 3g).
Tubular apoptosis
Apoptotic RPTCs were more abundant in Tg (Figure 4b)
than non-Tg mice (Figure 4a). Apocynin (Figure 4c) and
perindopril (Figure 4d) effectively attenuated RPTC apopto-
sis, whereas hydralazine was without effect (Figure 4e).
Semiquantitative estimation of the number of apoptotic
RPTCs confirmed these findings (Figure 4f). Apoptotic
RPTCs were detected in at least 16 and 3% of tubules at
the glomerulo-tubular (G-T) junction in Tg and non-Tg
kidneys, respectively (Figure 4g). Treatment with apocynin or
perindopril significantly reduced the number of apoptotic
RPTCs at the G-T junction to 4 and 3%, respectively, whereas
hydralazine had little effect (14%).
Immunohistochemistry revealed increased staining for
active caspase-3 (Figure 5b) and Bax (Figure 5g) in RPTCs of
Tg mice compared to non-Tg mice (Figure 5a and f).
Treatment with apocynin (Figure 5c and h) or perindopril
(Figure 5d and i) effectively attenuated these changes,
whereas hydralazine had no effect (Figure 5e and j). Similar
trends were observed in caspase-3 activity assays (Figure 5k)
and western blotting of Bax (Figure 5l) from isolated renal
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Figure 1 | ROS generation, urinary albumin/creatinine ratio,
and kidney/body weight ratio in male non-Tg and Tg mice
with or without apocynin, perindopril, or hydralazine
treatment. (a) ROS generation in RPTs; (b) Urinary albumin
(mg/ml)/creatinine (mg/100 ml) ratio; (c) Kidney-to-body weight
ratio. The kidney-to-body weight ratio was measured as the
weight of two kidneys per body weight. All data are expressed as
mean±s.d., N¼ 8 (*Po0.05; NS, not significant). Non-Tg (empty
bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H,
hydralazine.
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proximal tubules (RPTs). Taken together, these data demon-
strate that apocynin and the RAS blocker perindopril
effectively prevented RAS-induced RPTC apoptosis, whereas
hydralazine had minimal effect.
Tubulointerstitial fibrosis
Tg kidneys exhibited enhanced expression of extracellular
matrix proteins (Figure 6b), collagenous components (Figure
6g), and immunoreactive collagen type IV (Figure 6l) as
compared to the kidneys of non-Tg mice (Figure 6a, f and k).
These changes were attenuated by apocynin (Figure 6c, h and
m), perindopril (Figure 6d, i and n), and hydralazine (Figure
6e, j and o) as quantitated in sections stained with Masson’s
trichrome (Figure 6p) or immunoreactive collagen type IV
(Figure 6q).
Similarly, Tg kidneys also showed higher expression of
transforming growth factor-b1 (TGF-b1) and plasminogen
activator inhibitor-1 (PAI-1) (Figure 7b and g) than non-Tg
kidneys (Figure 7a and f). Treatment with apocynin (Figure
7c and h), perindopril (Figure 7d and i), or hydralazine
(Figure 7e and j) attenuated these changes. TGF-b1 and PAI-
1 expression was quantitated by western blotting (Figure 7k
and l).
Effect of apocynin and perindopril on Bax, Bcl-xL, TGF-b1,
and PAI-1 mRNA expression in Tg mice
Bax mRNA expression was significantly higher (Figure 8a),
whereas Bcl-xL mRNA expression was significantly lower
(Figure 8b) in Tg than in non-Tg RPTs. Treatment with
apocynin or perinodpril markedly reversed these changes,
whereas hydralazine had no detectable effects. In contrast, all
agents attenuated the increases in TGF-b1 mRNA (Figure 8c)
and PAI-1 mRNA (Figure 8d) expression in Tg RPTs.
Effect of apocynin on NADPH oxidase activity and p47phox
expression in Tg mice
ROS generation and NADPH oxidase activity were signifi-
cantly higher in Tg than in non-Tg RPTs (Figure 9a and b).
Treatment with apocynin effectively inhibited ROS genera-
tion and NADPH activity in Tg RPTs, but not in non-Tg
RPTs. Furthermore, phosphorylated (p)-p47phox and
p47phox expression in membrane (Figure 9c) and cytosolic
(Figure 9d) fractions of Tg RPTs was significantly higher in
Tg RPTs than in non-Tg RPTs. Apocynin effectively
attenuated p-p47phox and p47phox expression in membrane
fractions of Tg RPTs without affecting non-Tg RPTs (Figure
9c). In contrast, apocynin did not effect p-p47phox and
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Figure 2 | SBP in Tg and non-Tg mice. (a) Longitudinal changes in mean SBP in male non-Tg and Tg mice with or without apocynin,
perindopril, or hydralazine treatment for an 8-week period. Baseline SBP was measured in all mice for 5 days before the first SBP reading.
Non-Tg mice (E), Tg mice (’), and Tg mice treated with apocynin (J), perindopril (B), or hydralazine (&) starting at week 13. (b) Cross-
sectional analysis of SBP (measured 2–3 times per week in the morning without fasting, week 20) in non-Tg and Tg mice with or without
apocynin, perindopril, or hydralazine treatment. All data are expressed as mean±s.d., N¼ 8 (*Po0.05; **Po0.01; ***Po0.005; NS, not
significant). Non-Tg (empty bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H, hydralazine.
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p47phox expression in cytosolic fractions of Tg and non-Tg
RPTs (Figure 9d).
DISCUSSION
This study demonstrates that apocynin treatment prevents
RPTC apoptosis in Agt-Tg mice independently of systemic
hypertension. These findings indicate that ROS generation by
intrarenal RAS activation is likely important in the induction
of RPTC apoptosis.
Our Tg model specifically expresses Agt in RPTCs but not
in other tissues.31 Our data significantly demonstrate elevated
ROS generation in RPTs of these Tg mice compared to non-
Tg mice, consistent with previous reports on Ang II
induction of ROS generation in rat32 and human RPTCs.33
The observation that apocynin and perindopril blocked ROS
generation in RPTs of Tg mice, whereas hydralazine had no
effect, indicates that enhanced ROS generation and albumi-
nuria in Tg mice may be attributed to augmented intrarenal
RAS activation per se rather than to increased SBP. Unlike
hydralazine, both apocynin and perindopril reversed albu-
minuria in Tg mice.
Baseline SBP was significantly higher in Tg than in non-Tg
mice. Between weeks 12 and 20, the SBP in Tg mice rose on
average by 20 mm Hg (Po0.05) as compared to non-Tg mice
(mean SBP was 100 and 120 mm Hg in non-Tg and Tg mice,
respectively). Hydralazine and perindopril effectively attenu-
ated SBP after 1 week of treatment. Surprisingly, apocynin
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Figure 3 | (a–e) Hematoxylin/eosin (H/E) staining of kidneys of
male non-Tg mice and Tg mice with or without apocynin,
perindopril, or hydralazine treatment. (a) Non-Tg control; (b) Tg
mouse; (c) apocynin-treated Tg mouse; (d) perindopril-treated Tg
mouse; (e) hydralazine-treated Tg mouse. Original magnification,
 600. (f) Mean RPTC volume of male non-Tg and Tg mouse
kidneys with or without treatment at week 20. (g). Mean
glomerular volume of male non-Tg and Tg mouse kidneys with or
without treatment at week 20. Arrows indicate tubular damage,
i.e., RPTCs without brush border, presence of vacuoles or cellular
atrophy. A, apocynin; P, perindopril; H, hydralazine.
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Figure 4 | Apoptosis in male non-Tg and Tg mouse kidneys
with or without apocynin, perindopril, or hydralazine
treatment, analyzed by TUNEL assay. (a) Non-Tg control; (b) Tg
mouse; (c) apocynin-treated Tg mouse; (d) perindopril-treated Tg
mouse; (e) hydralazine-treated Tg mouse. Original magnification,
 600. Arrows indicate apoptotic cells in proximal tubules. (f) Bar
graph showing semiquantitative analysis of apoptotic RPTCs from
male non-Tg and Tg mouse kidneys with or without apocynin,
perindopril, or hydralazine treatment. (g) Bar graph showing
semiquantitative analysis of % of tubules with apoptotic RPTCs at
the glomerulo-tubular (G-T) junction of 20 glomeruli from male
non-Tg and Tg kidneys with or without apocynin, perindopril or
hydralazine treatment. Values are expressed as mean±s.d., N¼ 8
(*Po0.05; **Po0.01, ***Po0.005; NS, not significant). Non-Tg
(empty bars) and Tg (solid bars) mice. A, apocynin; P, perindopril;
H, hydralazine.
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did not lower SBP in Agt-Tg mice. Previous studies have
reported that apocynin decreased blood pressure in Dahl salt-
sensitive hypertensive rats,34 aldosterone-induced hyperten-
sive rats35 and Ang II-induced hypertensive rats.36 The
reasons for this apparent discrepancy are unknown. One
possible explanation is that Ang II derived from Agt in
RPTCs (that is, Ang II generated by RPTC renin and
angiotensin-converting enzyme in RPTCs37) might affect SBP
through direct vasoconstriction of glomerular arterioles by
the Ang II AT1-receptor independently of ROS generation.
This possibility is further supported by the observation that
hydralazine prevented hypertension in Tg mice without
ameliorating intrarenal abnormalities. Another possibility is
that apocynin is not effective in blocking the membrane
translocation of p-p47phox in glomerular arteriole smooth
muscle cells, although it does block the translocation of
p-p47phox in RPTs, as seen in our study. Indeed, Heumuller
et al.38 recently reported that apocynin is not an effective
inhibitor of vascular NADPH oxidase due to the absence of
myeloperoxidase in vascular smooth muscle cells to convert
apocynin into active apocynin dimer. In contrast, myelo-
peroxidase protein has been detected in RPTs of patients with
membranous glomerulopathy,39 consistent with formation of
active apocynin.
Although oxidative stress is associated with hypertension,
it remains unclear whether ROS could initiate the develop-
ment of hypertension. In clinical studies, treatment with
antioxidants failed to decrease high blood pressure.40,41
Likewise, apocynin did not affect hypertension in this study
but yet attenuated renal ROS generation. Thus, it is
conceivable that oxidative stress is not the cause but
rather a consequence of hypertension, such that blocking
ROS ameliorates the renal lesions from a downstream
point.
Our data highlight the importance of intrarenal Agt gene
expression and ROS generation in mediating RPTC hyper-
trophy and tubular apoptosis in the mouse kidney. Although
the relationship between RPTC hypertrophy and apoptosis is
not well understood, it is speculated that low cellular ROS
levels induce cell hypertrophy whereas high ROS levels evoke
cell apoptosis. Indeed, Griendling’s group and others have
shown that ROS stimulates both cellular hypertrophy and
apoptosis, depending on cellular ROS levels and their
molecular species.42,43
The numbers of terminal transferase-mediated deoxy-
uridine triphosphate nick-end-labeling (TUNEL)-positive
RPTCs were significantly higher in Tg than in non-Tg mice.
These data are consistent with previous reports concerning
Ang II induction of RPTC apoptosis both in vitro and in
vivo.33,44 Consistent with the TUNEL assay, RPTs of Tg mice
exhibited enhanced active caspase-3 and Bax expression.
These changes were attenuated by apocynin and perindopril
but not by hydralazine. Heightened Bax expression occurred
with concomitant downregulation of the Bcl-xL gene.
Apocynin and perindopril but not hydralazine reversed the
Bax/Bcl-xL ratio. An increased Bax/Bcl-xL ratio is consistent
with promotion of apoptosis, and is a likely mechanism by
which intrarenal RAS activation and ROS enhance tubular
apoptosis in Tg mice.
The precise mechanism(s) by which apocynin prevents
Ang II-induced ROS generation and subsequent tubular
injury (albuminuria, interstitial fibrosis, and RPTC apopto-
sis) in Tg mice is far from being fully understood. It has been
postulated that apocynin blocks NADPH oxidase assembly by
interfering with p-p47phox binding to gp91phox,45 as Ang II
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Figure 5 | Immunohistochemical staining of a-active caspase-3
(a–e) and Bax (f–j) in male non-Tg and Tg mouse kidneys with or
without apocynin, perindopril, or hydralazine treatment,
employing rabbit anti-a-active caspase-3 and anti-Bax antibodies
(1:50 dilution), respectively. (a–e, f–j) (a, f) non-Tg control; (b, g)
Tg mouse; (c, h) apocynin-treated Tg mouse; (d, i) perindopril-
treated Tg mouse; (e, j) hydralazine-treated Tg mouse. Original
magnification,  600. Arrows indicate caspase-3-stained cells
(a–e) or Bax-stained cells (f–j). (k) Caspase-3 activity in RPTs from
male non-Tg and Tg mouse kidneys with or without apocynin,
perindopril, or hydralazine treatment. (l) Western blot analysis of
Bax expression (antibody dilution 1:500) in mouse RPT extracts of
male non-Tg and Tg mice. All data are expressed as mean±s.d.,
N¼ 8 (*Po0.05, **Po0.01; NS, not significant). Non-Tg (empty
bars) and Tg (solid bars) mice. A, apocynin; P, perindopril; H,
hydralazine.
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activates protein kinase C and subsequently phosphorylates
p47phox.46 Indeed, our data support this notion. Likewise,
the mechanism(s) by which ROS induce RPTC apoptosis
remains undefined. One possibility is that ROS, through
activating p38 mitogen-activated protein kinase signaling,
stimulate p53 phosphorylation.47 Phosphorylated p53 then
translocates to the nucleus and enhances Bax gene transcrip-
tion.48,49 Bax translocates to the mitochondria and binds the
anti-apoptotic proteins Bcl-2 and Bcl-xL, inhibiting their
protective actions on gate-keeping and, ultimately, leading to
mitochondrial dysfunction and caspase-3 activation. Our
data on increased Bax and caspase-3 expression, combined
with decreased Bcl-xL expression in RPTs of diabetic Tg mice,
lend support to this notion. Furthermore, our data indicate
that enhanced intrarenal RAS activation stimulates Bax
mRNA and protein expression in Tg mice.
The present results may have clinical implications. As
tubular apoptosis is detectable in various renal diseases7–14
and tubular atrophy appears to be a better indicator of
disease progression than glomerular pathology,4,19,50,51 we
postulate that RPTC apoptosis may be an initial step leading
to tubular atrophy and that ROS is one of the key mediators
of this process.
In summary, our study indicates an important role for
ROS in albuminuria, interstitial fibrosis and RPTC apoptosis
in Agt-Tg mice independently of systemic hypertension
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Figure 6 | Periodic-acid Schiff (PAS) staining (a–e), Masson’s Trichrome staining (f–j), and collagen type IV immunostaining (k–o) of male non-
Tg and Tg mouse kidneys at week 20. (a–e), (f–j) and (k–o): (a,f,k) non-Tg control littermate; (b,g,l) Tg mouse; (c,h,m) Tg mouse treated with
apocynin; (d,i,n) Tg mouse treated with perindopril; (e,j,o) Tg mouse treated with hydralazine. Original magnification,  600. Arrows
indicate location of extracellular matrix (a–e), collagenous materials (f–j), and collagen type IV immunostaining (k–o). Quantification of
collagenous component accumulation (Masson staining) (p) and collagen IV deposition (q). Values are expressed as mean±s.d., N¼ 8 in
males (*Po0.05; **Po0.01; NS, not significant). A, apocynin; P, perindopril; H, hydralazine.
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in vivo. Our Tg mice may be a useful animal model to study
the mechanism(s) of Ang II action on ROS generation in the
kidney. Our data suggest that selective inactivation of renal
NADPH oxidase may provide a novel therapeutic target for
attenuating or reversing nephropathy, including tubular
atrophy, in various renal diseases.
MATERIALS AND METHODS
D(þ )-glucose, bovine serum albumin (fraction V), apocynin (4-
hydroxy-3-methoxyacetophenone, an orally active and selective
inhibitor of NADPH oxidase), hydralazine (a vasodilator), and
monoclonal antibodies against b-actin were purchased from Sigma-
Aldrich Canada Ltd (Oakville, ON, Canada). Perindopril (an
angiotensin-converting enzyme inhibitor) was obtained from
Servier Ame´rique (Laval, QC, Canada). Anti-cleaved caspase-3,
anti-Bax polyclonal antibody, and monoclonal anti-collagen type IV
antibody were procured from New England Biolabs Ltd (Pickering,
ON, Canada), BD Pharmingen (San Diego, CA, USA), and
Chemicon International Inc. (Temecula, CA, USA), respectively.
Protein G plus beads, anti-TGF-b1, anti-PAI, and anti-p47phox
polyclonal antibodies were purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA). Anti-phosphoserine monoclonal
antibody was obtained from BIOMOL International Inc. (Plymouth
Meeting, PA, USA). Normal glucose (5 mM) Dulbecco’s modified
Eagle’s Medium (Catalogue No. 12320) and 100 penicillin/
streptomycin were bought from Invitrogen Inc. (Burlington, ON,
Canada).
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Agt-Tg mice
Tg mice (C57Bl6 background, line no388) were created in our
laboratory (J.S.D.C.) by inserting rAgt cDNA fused with a HA tag (a
sequence encoding amino acid residues 98-106 (YPYDVPDYA) of
human influenza virus hemagglutinin) at the 30 terminal into a
construct containing the kidney-specific androgen-regulated protein
promoter specific to RPTCs.31 Non-Tg, sex-matched littermates
served as controls. All animals received standard mouse chow and
water ad libitum. The experimental procedures were approved by the
Animal Care Committee of the CHUM.
Physiological studies
Male adult Tg mice (age 8–10 weeks) were divided into 4 groups (8
mice per group): (1) Tg mice treated with sterile water sweetened
with NutraSweet; (2) Tg mice treated with apocynin (Sigma-Aldrich
Canada Ltd) at 2.4 g/l dissolved in sterile water (sweetened with
NutraSweet), as established by Susztak et al.;27 (3) Tg mice given
perindopril (4 mg/kg/day) in drinking water; (4) Tg mice given
hydralazine (15 mg/kg/day) in drinking water. Non-Tg littermates
receiving no drug or treated with apocynin served as additional
controls.
Three days after treatment, SBP was measured with a BP-2000
tail-cuff pressure device (Visitech Systems, Apex, NC, USA)31 in the
morning, at least 2–3 times a week for 10 weeks. The mice were
trained to this procedure for at least 15-20 min per day for 5 days
before the first SBP reading. SBP values represent the mean± s.d. of
2–3 determinations per week per group of animals.
All animals were killed at age 18–20 weeks. Twenty-four hours
before killing, they were housed individually in metabolic cages.
Body weight was recorded. Urine was collected and assayed for
albumin and creatinine (ELISA, Albuwell and Creatinine Compa-
nion; Exocell Inc., Philadelphia, PA, USA).31 Both kidneys were
removed, decapsulated, and weighed together. The left kidneys were
processed for histology and apoptosis study, and the right kidneys
were used for isolation of RPTs by Percoll gradient.31
Histological studies
Kidneys were collected in Tissue-Tek cassettes (VWR Canlab,
Montreal, QC, Canada), dipped immediately in ice-cold formalde-
hyde (10% in phosphate-buffered saline) and fixed for 24 h at 4 1C.
The cassettes were then processed by the CHUM Pathology
Department. Tissue blocks were cut with a microtome to obtain
the desired tissue specimens. Tissue sections (4–5 sections per
kidney) from eight animals per group were stained with hematox-
ylin/eosin or periodic acid Schiff or Masson’s trichrome. Masson’s
trichrome-stained images were quantified by NIH ImageJ software
(http://rsb.info.nih.gov/ij/). Briefly, 10–15 fields per animal were
randomly selected from each group. The collected images were
changed into 8-bit grayscale by the software. Then, a threshold was
determined to filter particles outside the color and intensity range.
This threshold was applied to all images, which were analyzed by
calculating the total area covered by colored particle deposition and
expressed as ‘arbitrary units’.
The mean volume of 30 random glomeruli per mouse was
assessed by Weibel’s method52 with Motic Images Plus 2.0 image
analysis software (Motic, Richmond, BC, Canada). RPTC volume
was measured from 100 RPTCs of 50 RPTs per mouse, respectively,
with the same software. Outer cortical RPTs with similar cross-
sectional views and clear nuclear structure were selected. Mean cell
volume was estimated by the Nucleator method.53
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Figure 8 | RT-qPCR assays of Bax (a), Bcl-xL (b), TGF-b1 (c) and PAI-1 (d) mRNA expression in RPTs of non-Tg and Tg mice with or without
apocynin, perindopril or hydralazine treatment. Bax, Bcl-xL, TGF-b1, PAI-1, and b-actin mRNAs were run simultaneously in the same RT-qPCR
assay. Bax, Bcl-xL, TGF-b1, and PAI-1 mRNA levels were normalized by corresponding b-actin mRNA levels. mRNA levels in non-Tg were
considered as 100%. All data are expressed as mean±s.d., N¼ 8 (*Po0.05, **Po0.01; NS, not significant). Non-Tg (empty bars) and Tg (solid
bars) mice. A, apocynin; P, perindopril; H, hydralazine.
Kidney International (2009) 75, 156–166 163
F Liu et al.: Apocynin and tubular apoptosis o r i g i n a l a r t i c l e
TUNEL assay and immunohistochemical staining
The percentage of apoptotic RPTCs (TUNEL kit; Roche Diagnostics,
Laval, QC, Canada) was estimated semiquantitatively.54,55 Briefly,
10–15 fields per animal were randomly selected from each group.
Then, the total number of apoptotic RPTCs was divided by the total
number of RPTCs counted and multiplied by 100 to derive the % of
apoptotic-positive RPTCs. Similarly, the % of G-T junctions
containing apoptotic RPTCs was quantified by counting the total
number of G-T junctions containing apoptotic RPTCs divided by
the total number of G-T junctions counted (approximately 20 G-T
junctions counted for each group) and then multiplied by 100.
Immunohistochemical staining was performed according to the
standard avidin-biotin-peroxidase complex method (ABC Staining
System; Santa Cruz Biotechnology Inc.).31,54 Collagen IV immuno-
stained images were quantified by NIH ImageJ software, as
described above for Masson’s trichrome staining.
ROS generation, NADPH oxidase activity, and caspase-3
activity assay
Aliquots of freshly isolated proximal tubules were prepared
immediately for ROS measurement by the lucigenin method.54,56
Briefly, RPTs were washed in modified Krebs buffer containing NaCl
(130 mM), KCl (5 mM), MgCl2 (1 mM), CaCl2 (1.5 mM), K2HPO4
(1 mM), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(20 mM), pH 7.4, and resuspended in 900 ml of Krebs buffer
supplemented with 1 mg/ml bovine serum albumin. The cell
suspension was transferred to plastic tubes and ROS production
was assessed in a luminometer (LB 9507; Berthold, Wildbad,
Germany). Measurement was started by an injection of 100ml
lucigenin (final concentration 5 10–4 M). Photon emissions were
counted every 1 min for up to 20 min. Peak emissions at 10 min
were recorded from each group for comparison. Modified Krebs
buffer served as a control (blank). Solutions containing lucigenin
without RPTs did not display any significant interference in the
lucigenin assay. ROS production in RPTs was normalized with
protein concentration and expressed as relative light units per mg
protein.
NADPH oxidase activity was measured by a luminescence
assay.35,57 Briefly, RPTs were homogenized in lysis buffer and
assayed in 50 mM phosphate buffer, pH. 7.0, containing 1 mM EGTA,
150 mM sucrose, 5 mM lucigenin, and 100mM NADPH (final volume,
0.9 ml). The reaction was started after the addition of 100 ml
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Figure 9 | ROS generation, NADPH oxidase activity, and western blotting of p47phox in RPTs of non-Tg and Tg mice with or without
apocynin treatment. (a) ROS generation; (b) NADPH oxidase activity; (c) western blotting of p-p47phox and p47phox in membrane
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(B100 mg) of homogenate protein. No activity was detected in the
absence of NADPH.
Caspase-3 activity was assayed on frozen (80 1C) mRPTs with
caspase-3 assay kits (BD Bioscience Pharmingen, Mississauga, ON,
Canada), as described previously.54
Cellular fractionation
RPTs were fractionated to membrane and cytosolic fractions by the
method of Medhora et al.58 Briefly, RPTs were sonicated for 8 s on
ice in 25 mM Tris-HCl buffer, pH 7.4, containing 1 mM EDTA, 1 mM
EGTA and a cocktail of protease inhibitors (10 mg/ml aprotinin,
0.5mg/ml leupeptin, 0.7mg/ml pepstatin, and 0.5 mM phenylmethyl-
sufonyl fluoride). Following centrifugation at 18,200 g (13,600 rpm)
for 10 min at 4 1C, pellets containing the membrane fraction were
solubilized with radioimmuno precipitation assay buffer (50 mM
Tris-HCl, pH. 7.4, containing 150 mM NaCl, 0.25% deoxycholic acid,
1% NP-40, 1 mM EDTA, and a cocktail of protease inhibitors).
Immunoprecipitation, western blotting, and real-time
quantitative polymerase chain reaction assays
for gene expression
Immunoprecipitation of membrane and cytosolic fractions was
performed as the following: Briefly, 200mg of membranous or
cytosolic fraction was incubated with 1 mg anti-p47phox antibody
for 3 h at 4 1C with agitation. Then, 50 ml of Protein G plus beads
was added to each sample and further agitated for overnight at 4 1C.
Then, the mixture was centrifuged and beads were washed 3 times in
lysis buffer. Finally, 20 ml of 2 loading buffer was added to the
beads, boiled at 95 1C for 5 min, and subjected to SDS–polyacryla-
mide gel electrophoresis. Western blotting for Bax, TGF-b1, PAI-1,
p47phox, and phosphoserine was performed as described else-
where.31,54 Bax, Bcl-xL, TGF-b1, and PAI-1 mRNA expression in
mRPTs was quantified by real-time quantitative PCR with forward
and reverse primers corresponding to the respective genes
(Table 1).54
Statistics
Data were expressed as mean±s.d. and analyzed by one-way
ANOVA and the Bonferroni test. Po0.05 values were considered
significant.
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